CCRM Nordic: 2025 Year in Review
2025 was a defining year for CCRM Nordic. As our CEO Fredrik Wessberg notes, we have moved from ambition to execution.
Our mission remains clear: You create the future of advanced therapies; we make the road there smoother. By addressing critical bottlenecks in the translation and commercialization of ATMPs, we are bringing life-changing treatments closer to the patients who need them.
Here is a selection of highlights of how we strengthened the Nordic and European ATMP ecosystem this past year.
-
Technical delivery & workflows
We successfully established automated, end-to-end immuno-oncology workflows and set up our first stem cell workflow. We’ve managed to start generating data and delivered our first customer projects. Together with our integrated CMC design strategy, these technical foundations are critical for building scalable, cost-effective and market-viable manufacturing strategies for the clinic and beyond.
Building future capacity
Our infrastructure plans are now a reality. We have completed facility design qualification and advanced the cration of our 3,000 m² state-of-the-art facility, which is on track for move in mid 2026 and GMP opening in 2027.
Ecosystem & workforce impact
With over 4,000 beneficiaries in our 2025 programs, we are actively closing the ATMP talent gap through the launch of SCALE. Additionally, we’ve taken our seat at the table in EU ATMP policy dialogues to advocate for Nordic innovators and orchestrated a number of events.
-
Strategic growth
Collaboration is our core. In 2025, we launched 8 new collaborations and made our first venture investment. Our partners, from AstraZeneca to Verigraft, recognize CCRM Nordic as a powerhouse for tackling real-world development challenges.
The full report contains detailed case studies, employee perspectives, and our strategic outlook for 2026–27.
Download the full 2025 Year in Review here.
Ready to collaborate? Contact us at info@ccrmnordic.se.